Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter, Caroline Robert(Institut Gustave Roussy), Adil Daud(University of California, San Francisco), Omid Hamid(Cedars-Sinai Medical Center), Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States)), Catriona M. McNeil(Chris O’Brien Lifehouse), Jean‐Jacques Grob(Aix-Marseille Université), Paul Lorigan(Manchester Academic Health Science Centre), Georgina V. Long(The University of Sydney), Michal Lotem(Hadassah Medical Center), James Larkin(Trinity College Dublin), Laurent Mortier, Bart Neyns(Universitair Ziekenhuis Brussel), Matteo S. Carlino(The University of Sydney), Antoni Ribas(University of California, Los Angeles), Christian U. Blank(The Netherlands Cancer Institute), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Teresa M. Petrella, Ana Arance(Hospital Clínic de Barcelona)
Cited by 1,247
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k